The molecular tumor board as a step in cancer patient management: a southern Italian experience.

ABSTRACT:

Introduction

The management of cancer patients follows a Diagnostic Therapeutic and Care Pathway (PDTA) approach, aimed at achieving the optimal balance between care and quality of life. To support this process, precision medicine and innovative technologies [e.g., next-generation sequencing (NGS)] allow rapid identification of genetic-molecular alterations useful for the design of PDTA-approved therapies. If the standard approach proves inadequate, the Molecular Tumor Board (MTB), a group comprising specialists from diverse disciplines, can step in to evaluate a broader molecular profile, proposing potential therapies beyond evidence levels I-II or considering enrolment in clinical trials. Our aim is to analyze the role of the MTB in the entire management of patients in our instit

SUBMITTER: Tommasi S 

PROVIDER: S-EPMC11422073 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature